You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科笛-B(02487.HK):CU-40102(外用非那雄胺噴霧劑)獲國家藥監局上市批準
格隆匯 06-30 17:17

格隆匯6月30日丨科笛-B(02487.HK)發佈公告,集團的CU-40102(外用非那雄胺噴霧劑)已獲得中國國家藥品監督管理局(“國家藥監局”)上市批準。CU-40102獲批的適應症爲治療雄激素性脫髮,其是全球首個亦是唯一一個獲批用於雄激素性脫髮治療的外用非那雄胺,也是中國首個且唯一一個獲批上市的外用非那雄胺。

非那雄胺作爲特異性II型5α-還原酶競爭抑制劑抑制頭皮中睾酮轉化爲雙氫睾酮,可治療雄激素性脫髮。與口服非那雄胺不同,CU-40102的外用製劑便於患者將藥物直接精確地塗抹在頭皮表面,與口服藥比較,可降低藥物的全身暴露。集團相信CU-40102作爲外用藥將更容易被患者接受,爲雄激素性脫髮患者提供一種替代解決方案,成爲患者新的用藥選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account